Trial
NCT03723915
Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Northwestern University
Collaborators
National Cancer Institute (NCI)
Condition
Pancreatic Adenocarcinoma
Intervention
Pembrolizumab
Why stopped
The total accrual goal of 34 patients was not met. Stage 1 of the study did not meet the interim analysis criteria to move onto Stage 2 of the Simon 2 stage design.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-10-05